Back to Press Releases

Revance and Teoxane Announce RHA® Dynamic Volume is Available Now

FDA-approved for cheek augmentation and/or age-related midface contour deficiencies, in adults aged 22 years or older, RHA® Dynamic Volume delivers natural-looking results by addressing volume loss in both dynamic superficial fat and static deep fat¹⁻²

Nashville, TN – March 24, 2026 – Revance and Teoxane announce today that RHA® Dynamic Volume, formerly RHA® 4 Mepi, is now available. RHA® Dynamic Volume is a product designed with unique rheology to adapt to facial movements and deliver natural-looking results.³ As aesthetic medicine continues to evolve, patients increasingly seek treatments that enhance natural beauty.

Now FDA-approved for cheek augmentation and/or age-related midface contour deficiencies, RHA® Dynamic Volume offers providers the option to address volume loss by restoring both dynamic superficial fat, which moves with facial expressions, and/or static deep fat, which provides foundational support, for up to one year.1,3-4 Additionally, weight loss medications can induce facial fat loss leading many to seek natural-looking restoration of facial volume.

“RHA® Dynamic Volume represents the next chapter of the Teoxane RHA® Collection,” shared Nadeem Moiz, CEO of Revance. “This launch underscores the product’s ability to meet the growing demand for fillers that deliver natural-looking, dynamic results. With the expanded midface indication, RHA® Dynamic Volume continues to set the standard for facial rejuvenation by combining adaptability, resiliency, and long-lasting results.”

Using Teoxane's ATP approach (Anatomy, Assessment & Aging, Technique, Product) and the Teoxane MLT Multilayering Technique™, providers can achieve precise, tailored results while prioritizing safety by avoiding high-risk vascular zones.3,5-6 RHA® Dynamic Volume, paired with the Teoxane MLT Multilayering Technique™, addresses midface volume loss by restoring deep structural support and enhancing superficial dynamic contours, delivering tailored, natural-looking results.3,7-8

“RHA® Dynamic Volume represents a strong demonstration of our commitment to uniting advanced technology, scientific excellence, and a truly patient‑centered approach to facial rejuvenation,” said Can Ongen, COO at Teoxane. “When combined with Teoxane’s MLT Multilayering Technique™, RHA® Dynamic Volume provides natural‑looking midface results that align with the expectations of today’s aesthetic patients.”

Patient satisfaction data further demonstrates the effectiveness of RHA® Dynamic Volume. In clinical studies, approximately 98% of patients reported natural-looking results in the midface at 2 months, while over 94% reported natural-feeling results at rest and in motion at 1 year.2 In clinical trials, RHA® Dynamic Volume demonstrated a favorable safety profile, with no late-onset or serious treatment-related adverse events, and no events deemed to be granulomas or delayed inflammatory responses.

“RHA® Dynamic Volume is an innovation for patients experiencing volume loss due to weight changes or aging in the midface, delivering results that are beautiful at rest and in motion,” said board-certified dermatologist Dr. Jody Comstock. “It’s a versatile option that allows me to tailor treatments to each patient’s unique needs.”

Learn more about the Teoxane RHA® Collection at rha.revanceaesthetics.com.

About Revance:

Revance is a global company developing, producing, and distributing industry-leading, differentiated products across aesthetics, skincare, and therapeutics. Revance drives innovation beyond convention to offer treatment options for individuals across generations. The Company’s vision is to redefine excellence in aesthetics, skincare, and therapeutics through science-powered innovation, with an unwavering commitment to its providers, patients, and consumers. Revance’s award-winning products are the result of robust research and development, a cornerstone for the Company, driven by renowned scientists. For more information about Revance, please visit us at www.revance.com.

About Teoxane:

Founded by Valérie Taupin in 2003, Teoxane specializes in developing solutions using hyaluronic acid. With over 20 years of expertise, it is a pioneer in the science of facial beauty. The company was founded on a unique vision: to open the possibilities of aesthetic treatments using high-performance dermal and dermo-cosmetic fillers developed through in-depth scientific research. Through attentive listening, education and establishing the foundations for a safer industry, Teoxane has ushered in a new era in aesthetic medicine. Here, minor beauty procedures wield a significant impact on a patient’s self-image and overall well-being.

www.teoxane.com

Media Contact:

EvolveMKD

Revance@EvolveMKD.com

References: 1. RHA® Dynamic Volume Directions for Use. 2025. 2. Data on File. TEO-® -2004. Geneva, Switzerland, Teoxane S.A., 2025. 3. Trévidic et al. Aesthet Surg J. 2022;42(8):920-934 4. Swift A, Liew S, Weinkle S, Garcia JK, Silberberg MB. The facial aging process from the “inside out.” Aesthet Surg J. 2021;41(10):1107-1119. 5. Flégeau et al. Plast Reconstr Surg Glob Open. 2025 ;13(2):e6560 6. Trévidic et al. Plast Reconstr Surg. 2022;149(6):1326-1336 7. Galadari H, Wienkle SH. Injection techniques for midface volumization using soft tissue hyaluronic acid fillers designed for dynamic facial movement. J Cosmet Dermatol. 2022;21(3):924-932. 8. Rohrich et al. Published Abstract at Masters of Aesthetics Symposium 2025


IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) injection, Teoxane RHA® Collection, and SkinPen®

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines...

DAXXIFY® (daxibotulinumtoxinA-lanm) injection IMPORTANT SAFETY INFORMATION

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION


Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency units of DAXXIFY® are not interchangeable with preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:
Glabellar lines (≥1%): headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Cervical dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

[DAXI-004726]

The long-term efficacy and safety outcomes of RHA® with lidocaine are applicable to RHA® with mepivacaine and mepivacaine has shown no significant impact on gel properties, including rheology and degradation profile.

PLEASE SEE FULL DIRECTIONS FOR USE

RHA® Collection of Fillers, by Teoxane

Indications


The Teoxane RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA Redensity®, RHA® 2, RHA® 3 and RHA® 4 with lidocaine and RHA Redensity® Mepi, RHA® 2 Mepi, RHA® 3 Mepi and RHA® Dynamic Volume, with mepivacaine.

RHA Redensity® and RHA Redensity® Mepi are indicated for injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids in adults 22 or older. RHA® 2 and RHA® 2 Mepi are indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) in adults 22 or older. RHA® 3 and RHA® 3 Mepi are indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) and is also indicated for injection into the vermillion body, vermillion border and oral commissure to achieve lip augmentation and lip fullness in adults 22 or older. RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) in adults 22 or older. RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs) and for injection into the subcutaneous to supraperiosteal layers for cheek augmentation and/or correction of age-related midface contour deficiencies in adults 22 or older.

IMPORTANT SAFETY INFORMATION


Contraindications


Do not use in patients who have severe allergies, marked by a history of anaphylaxis or multiple severe allergies, or in patients with a history of allergies to gram-positive bacterial proteins or local anesthetics of the amide type, such as lidocaine and mepivacaine.

Do not use in patients with bleeding disorders.

Warnings


Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures.

Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur.

Product use at specific sites in which an active inflammatory process or infection is present should be deferred until the underlying process has been controlled.

Precautions


These products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy.

Discuss the potential risks of soft-tissue injections with your patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications.

The safety and effectiveness for the treatment of anatomic regions other than the labeled indications have not been established in controlled U.S. clinical studies

As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Standard precautions associated with injectable materials should be followed.

The safety for use in sites in the presence of other implants, during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied.

Use with caution in patients on immunosuppressive therapy.

Patients who are using products that can prolong bleeding (such as thrombolytics, anticoagulants, or inhibitors of platelet aggregation) may experience increased bruising or bleeding at treatment sites.

Patients with a history of herpetic eruptions may experience reactivation of the herpes.

There is a possible risk of inflammation at the implant site if laser treatments or a chemical peel are performed after treatment.

Use as supplied. Modification or use of the product outside the Directions for Use may adversely impact the sterility, safety, homogeneity, or performance of the product.

For single patient use. Do not reuse a syringe between two treatments and/or between two patients. Do not resterilize.

Adverse Events


The most commonly reported side effects were firmness, redness, tenderness, swelling, lumps/bumps, bruising, discoloration, pain and itching. Most of these events were mild or moderate and resolved within 14 days.

Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own.

To report an adverse event with any RHA® product to Revance, please visit Safety.Revance.com or call at 1 (877) 373-8669.

RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.

Available by Prescription only

RHA-00221

The SkinPen system is a microneedling device and accessories intended to be used as a treatment to improve the appearance of wrinkles of the neck for Fitzpatrick skin types II – IV and to improve the appearance of facial acne scars in adults with all Fitzpatrick skin types aged 22 years and older. Rx only. To view SkinPen intended use, important safety information, and clinical trial details (data on file), contact us at regenerativemarketing@revance.com.

SkinPen®

Indications for Use

The SkinPen® Precision Elite, SkinPen® Precision and MicroPen EVO™ systems are microneedling devices and accessories intended to be used as a treatment to improve the appearance of wrinkles of the neck for Fitzpatrick skin types II - IV and to improve the appearance of facial acne scars in adults with all Fitzpatrick skin types aged 22 years and older. Indications and body treatment areas may vary based on your country.

Contraindications

The use of the SkinPen® Precision Elite, SkinPen® Precision and MicroPen EVO™ systems should not be used on patients who have active skin cancer in the treatment area(s), have open wounds, sores, or irritated skin in the treatment area(s), have an allergy to stainless steel or anesthetics, have a hemorrhagic (bleeding) disorder or hemostatic (bleeding) dysfunction, are pregnant or nursing, are currently taking drugs with the ingredient isotretinoin (such as Accutane®). Note: These products are not intended for transdermal (under the skin) delivery of topical products such as cosmetics, drugs, or biologics. For full safety information, instructions for use manual and clinical trial details, as applicable, visit us at skinpen.com and micropenevo.com.

Instagram LinkedIn

©2026 REVANCE. RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by REVANCE. All other trademarks are the property of their respective owners. CORP-00147

Intended for U.S. audiences

California Compliance DeclarationPrivacy PolicyTerms of UseMap policyHealth Data Privacy Policy